Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.310
+0.030 (2.34%)
At close: May 14, 2026, 4:00 PM EDT
1.310
0.00 (0.00%)
After-hours: May 14, 2026, 8:00 PM EDT
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees did not change compared to the previous year.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$191,935
Profits / Employee
-$833,844
Market Cap
326.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | 0 | - | 72 | 5 |
| Dec 31, 2024 | 77 | 2 | 2.67% | 70 | 7 |
| Dec 31, 2023 | 75 | -3 | -3.85% | 68 | 7 |
| Dec 31, 2022 | 78 | 17 | 27.87% | 70 | 8 |
| Dec 31, 2021 | 61 | 6 | 10.91% | 57 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Bicycle Therapeutics | 288 |
| C4 Therapeutics | 104 |
| Neumora Therapeutics | 96 |
| Rezolute | 75 |
| Armata Pharmaceuticals | 60 |
| Immuneering | 53 |
| Compass Therapeutics | 39 |
LCTX News
- 2 days ago - Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c) - TheFly
- 2 days ago - Lineage Cell Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 2 days ago - Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 2 days ago - Options Volatility and Implied Earnings Moves Today, May 12, 2026 - TipRanks
- 9 days ago - Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Business Wire
- 10 days ago - Lineage Cell announces 36-month results from Phase 1/2a study of RG6501 - TheFly
- 10 days ago - OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Business Wire
- 16 days ago - Lineage Cell Therapeutics initiated with a Buy at Canaccord - TheFly